A Japanese biotech founder closed U.S. funding through a network Merito built over seventeen years.

The challenge

A Japanese biotech founder needed U.S. investors who understood the science and had the capital to fund real growth, not just curiosity.

What Merito did

Merito built the target list, rebuilt the pitch around what U.S. life science funds actually underwrite, and ran the introductions through a network built over 17 years of business diplomacy.

The outcome

The company closed funding from U.S. investors and now holds a standing relationship with the American capital base its competitors still cannot reach.